Yesterday’s Capital Markets Day highlighted the substantial clinical unmet need in the management of erectile dysfunction (ED), and provided further confidence that MED2005 (topical ED therapy in Phase III) is a differentiated product with significant commercial potential in prescription and, over time, OTC markets. We look forward to top-line Phase III results expected in December 2019e, and reiterate our positive stance.
12 Feb 2019
Feedback from successful Capital Markets Day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Feedback from successful Capital Markets Day
Futura Medical plc (FUM:LON) | 35.5 -0.4 (-2.7%) | Mkt Cap: 107.0m
- Published:
12 Feb 2019 -
Author:
Dr Jens Lindqvist -
Pages:
3
Yesterday’s Capital Markets Day highlighted the substantial clinical unmet need in the management of erectile dysfunction (ED), and provided further confidence that MED2005 (topical ED therapy in Phase III) is a differentiated product with significant commercial potential in prescription and, over time, OTC markets. We look forward to top-line Phase III results expected in December 2019e, and reiterate our positive stance.